Fusion Protein Composition Comprising Receptor for Advanced Glycated Endproducts (RAGE) polypeptide

Abstract

The invention relates to a composition comprising a lyophilized mixture of a lyoprotectant, a Receptor for Advanced Glycation Endproducts (RAGE) fusion protein, and a buffer, wherein the RAGE fusion protein comprises a RAGE polypeptide directly linked to a polypeptide comprising a CH2 domain of an immunoglobulin or a portion of a CH2 domain of an immunoglobulin, and wherein the RAGE polypeptide comprises a RAGE ligand binding site, wherein the lyoprotectant comprises a non-reducing sugar, and wherein the amount of buffer is sufficient to provide a reconstituted composition having a pH ranging from 6.0 to 6.7 when the concentration of the RAGE fusion protein in the reconstituted composition is within the range from 1 mg / mL to 400 mg / mL. And the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.